SG10201803473WA - Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide - Google Patents

Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Info

Publication number
SG10201803473WA
SG10201803473WA SG10201803473WA SG10201803473WA SG10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA
Authority
SG
Singapore
Prior art keywords
methods
binding polypeptide
immunosuppressive therapy
alpha beta
tcr
Prior art date
Application number
SG10201803473WA
Inventor
Gregor Blank
Rupert Handgretinger
Karin Schilbach
Gina Lacorcia
Daniel Snell
Andreas Menrad
Original Assignee
Genzyme Corp
Univ Eberhard Karls Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Univ Eberhard Karls Tuebingen filed Critical Genzyme Corp
Publication of SG10201803473WA publication Critical patent/SG10201803473WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE 5 The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ -TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-αβ -TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel 10 methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibod ies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibod ies and/or fragments thereof) to reduce  T cells in the subject relative to γδ T cells in the subject are provided. 15 [No Figure]
SG10201803473WA 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide SG10201803473WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361897809P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
SG10201803473WA true SG10201803473WA (en) 2018-06-28

Family

ID=52021413

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603193PA SG11201603193PA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
SG10201803473WA SG10201803473WA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201603193PA SG11201603193PA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Country Status (8)

Country Link
US (2) US11142575B2 (en)
EP (1) EP3063174B1 (en)
CN (1) CN106795220A (en)
AU (2) AU2014342182B2 (en)
CA (1) CA2928756A1 (en)
MX (1) MX384246B (en)
SG (2) SG11201603193PA (en)
WO (1) WO2015066379A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
MX384246B (en) * 2013-10-30 2025-03-14 Genzyme Corp Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US20180298099A1 (en) * 2015-09-16 2018-10-18 Harry C. Ledebur, Jr. T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions
CN108070644B (en) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 Diagnosis system for gestational hypertension
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
AU2018295994B2 (en) * 2017-07-07 2025-02-06 Hanmi Pharm. Co., Ltd. Novel therapeutic enzyme fusion protein and use thereof
CN109777778B (en) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 A Genetically Modified γδT Cell
DE102017127984B4 (en) * 2017-11-27 2019-12-05 Immatics US, Inc. Method for the propagation and activation of γδ T cells
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (en) 2019-02-21 2024-11-29 马伦戈治疗公司 Antibody molecules that bind to NKP30 and uses thereof
CN120192414A (en) * 2019-04-03 2025-06-24 建新公司 Anti-αβTCR binding polypeptides with reduced fragmentation
WO2021097325A1 (en) * 2019-11-14 2021-05-20 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2023007133A (en) 2020-12-17 2023-06-27 Hoffmann La Roche Anti-hla-g antibodies and use thereof.
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh BMA031 antigen-binding polypeptides
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
CN118108842A (en) * 2023-06-09 2024-05-31 浙江大学 Humanized anti-CD24 antibody and its application

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050058641A1 (en) 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
BRPI0806340B8 (en) 2007-01-09 2021-05-25 Biogen Idec Inc isolated antibody that specifically binds to sp35, its use and pharmaceutical composition
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9018006B2 (en) * 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
UY34317A (en) * 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
MX384246B (en) * 2013-10-30 2025-03-14 Genzyme Corp Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Also Published As

Publication number Publication date
MX384246B (en) 2025-03-14
CN106795220A (en) 2017-05-31
AU2014342182B2 (en) 2020-05-14
EP3063174B1 (en) 2020-12-09
US20220098299A1 (en) 2022-03-31
MX2016005687A (en) 2017-03-30
AU2014342182A1 (en) 2016-05-19
SG11201603193PA (en) 2016-05-30
CA2928756A1 (en) 2015-05-07
WO2015066379A2 (en) 2015-05-07
WO2015066379A3 (en) 2015-07-09
AU2020217395A1 (en) 2020-09-03
US11142575B2 (en) 2021-10-12
US20160244523A1 (en) 2016-08-25
EP3063174A2 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
CR20200014A (en) POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
MX2020003046A (en) Anti-hla-a2 antibodies and methods of using the same.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
NZ628314A (en) Cd47 antibodies and methods of use thereof
MX2015013194A (en) TREATMENT OF CANCER USING A HUMANIZED ANTI-CD19 ANTIGEN CHEMICAL RECEPTOR.
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
MX2015003150A (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
HK1207655A1 (en) Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
MX2016015389A (en) Antibodies binding to human and cynomolgus cd3 epsilon.
NZ604007A (en) Monoclonal antibodies against her2 epitope
WO2014011993A3 (en) Epitope spreading associated with car t-cells
MX2015014017A (en) Fc region variant.
BR112012018914A2 (en) "humanized antibody, antigen binding protein, nucleic acid molecule, expression vector, recombinant host cell, antibody or antigen binding protein, methods for producing an antigen binding protein and for treating a subject affected by an autoimmune or inflammatory disease, and, pharmaceutical composition. "
MX2016005765A (en) Anti-il-17 antibodies, method for producing same and method for using same.
UA117097C2 (en) B1 BADYCININE ANTIBODY ANTIBODY
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2014185908A3 (en) Hybridoma clones, monoclonal antibodies, and methods of use
ZA202205383B (en) Novel anti-nogo-a antibodies
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
HK1227898A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide